Idorsia (Debt Restructuring)
Funding Details
Awarder
Inbox
Date Award
May 18, 2025
Vertical
Biopharmaceuticals
Funding URL
View Funding Page
Funding Amount
$150,000,000
Company Info
Traction
Sales of QUVIVIQ (daridorexant) reached CHF 61 million, with projections of approximately CHF 110 million in 2025.
Revenue Amount
$113,000,000
Market
Healthcare
Location
Allschwil, Switzerland
Company Description

The purpose of Idorsia is to discover, develop and commercialize innovative medicines to help more patients.

Links
WebsiteCrunchbaseLinkedInTwitter
Back to HomeBack to Biopharmaceuticals DealsView Funding Announcement